Central Retinal Vein Occlusion

Overview of diagnosis and treatment of central retinal vein occlusion.

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.

Lucentis for Central Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Central Retinal Vein Occlusion

Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.


Central Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Central Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Retinal Vein Occlusion Market Analysis Revealing Key Drivers & Growth Trends through 2023
Medgadget (blog)
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment and end user. On the basis the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis of ...

and more »

Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in ...
GlobeNewswire (press release)
Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion ... This bleeding and macular edema can affect central vision. According to a 2010 study published in the ...


IOP spikes more likely after treatment in certain patients
Healio
Patients with uveitis had the greatest mean IOP spike (24.3 mm Hg) compared with patients with central retinal vein occlusion (21.8 mm Hg), branch retinal vein occlusion (21.1 mm Hg) and (20.7 mm Hg) after a single injection. – by Robert Linnehan.


Find Market Research By Abhishek Budholiya (press release) (blog)

Retinal Vein Occlusion Therapeutics Market to Hold a High Potential for Growth by 2021
Find Market Research By Abhishek Budholiya (press release) (blog)
The RVO is mainly of two types based on the anatomy of the vein occlusion. The two types are branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). The BRVO occurs when the vein in the distal retinal system gets occluded ...


Clearside Biomedical (CLSD) Reports Complete Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in ...
StreetInsider.com
RVO is a particularly aggressive eye disease resulting from an occlusion in a vein carrying blood out of the retina. This blockage can lead to the rapid onset of symptoms, including sudden declines in vision. SAPPHIRE, a multicenter, multi-country ...


StockNewsTimes

MML Investors Services LLC Increases Holdings in Regeneron Pharmaceuticals Inc (REGN)
StockNewsTimes
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Take eye 'blackouts' seriously, doctor urges
Taipei Times
An eye stroke is caused by the occlusion of retinal veins in the center of the retina, which may lead to edema of the macular region, Hsu said, adding that the blurry vision, or even possible loss of sight, is due to lack of oxygen to the photoreceptor ...


Ocular Diagnostic Agents Market Boosting the Healthcare Industry Worldwide 2018 – 2026
Truthful Observer
In Europe, the incidence of diabetic retinopathy, glaucoma, and retinal vein occlusion is increasing among the geriatric population. It is a factor projected to propel the market in the region during the forecast period. According to a ... Rise in the ...


Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in ...
Dove Medical Press
... months after the first injection included Snellen best-corrected visual acuity (BCVA), central retinal thickness (CRT) by time-domain optical coherence tomography (TD-OCT) or spectral-domain optical coherence tomography (SD-OCT), anti-VEGF ...

and more »

Bel Marra Health

Central retinal vein occlusion (CRVO): Types, causes, symptoms, and treatment
Bel Marra Health
Central retinal vein occlusion (CRVO) refers to a medical condition of the eye where the main vein of the retina has become blocked. Much like other organs of the human body, our eyes also require a constant supply of oxygenated blood supplied by ...


Retinal Vein Occlusion Therapeutics Market Insights June 2018 covering Market Share, Market Concentration Rate ...
satPRnews (press release)
In this report the Global Retinal Vein Occlusion Therapeutics Market is valued (valuation provided in sample report) million in 2018 and is expected to reach USD (forecast provided in sample report) million by end of 2025, growing at a CAGR of ...


Week Herald

Regeneron Pharmaceuticals Inc (REGN) Shares Sold by Wells Fargo & Company MN
Macon Daily
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
form4.xml - SEC.govSEC.gov

all 53 news articles »

WPLG Local 10

Vasular condition leads to sudden sight loss
WPLG Local 10
Burgess was diagnosed with central retinal vein occlusion, or CRVO, a condition that causes a clot to form in the eye, leading to damaging pressure. "It was like someone threw a tomato at my eye," Burgess said. Cardiologist Dr. Adam Splaver said CRVO ...


StockNewsTimes

Mn Services Vermogensbeheer BV Increases Stake in Regeneron Pharmaceuticals Inc (REGN)
StockNewsTimes
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
Regeneron Unknown: Eylea Future Competition EffectsSeeking Alpha
Kiniksa Pharmaceuticals IPO: Cash KingSeeking Alpha
SEC.gov
all 129 news articles »

Bel Marra Health

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment
Bel Marra Health
There are two types of retinal veins. We have one central vein as well as several smaller branch veins. There are also two types of retinal vein occlusion: central retinal vein occlusion and branch retinal vein occlusion. The only difference between ...


Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to ...
Markets Insider
Ozurdex® is the first approved intravitreal injection for RVO in China and is licensed for the treatment of macular edema following BRVO and CRVO. Allergan has accelerated access to this treatment in 27 hospitals across China, making it available as a ...


Ozurdex for retinal vein occlusion approved in China
Healio
The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein occlusion, according to a press release from Allergan. Ozurdex (dexamethasone intravitreal ...


Regeneron Pharmaceuticals Inc (REGN) Given Average Rating of “Hold” by Brokerages
The Ledger Gazette
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.


Cardiovascular Business

Researchers confirm link between retinal vein occlusion, heart attack
Cardiovascular Business
The researchers further divided the RVO group into individuals with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Compared to people with neither form of RVO, the adjusted hazard ratios for CRVO and BRVO were 1.35 and ...


Targeted Oncology

Responses Found in Advanced Urothelial Carcinoma With FGFR Inhibitor
Targeted Oncology
According to a phase II study, over 40% of patients with metastatic or unresectable urothelial carcinoma responded to treatment with the investigational fibroblast growth factor receptor (FGFR) inhibitor erdafitinib. Findings from this study were ...

and more »

Medgadget (blog)

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and ...
Medgadget (blog)
Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein occlusion market offering a huge growth opportunity to the market players. Moreover, the ...

and more »

Ophthalmic Lasers Market: Global Analysis By Product (Diode, Femtosecond, Excimer, Nd:YAG, SLT), By Application ...
satPRnews (press release)
... share and growth rate of Ophthalmic Lasers in each applications: Age related Macular Degeneration, Central Serous Chorioretinopathy, Diabetic Retinopathy, Ocular Histoplasmosis, Ocular Tumors, Retinal breaks and detachment Retinal Vein Occlusion .

and more »

Ostrum Asset Management Buys Shares of 314 Regeneron Pharmaceuticals Inc (REGN)
Enterprise Leader
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related ...
Dove Medical Press
... short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal vein occlusion (CRVO).


Dispatch Tribunal

Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion
GlobeNewswire (press release)
... Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 3 clinical trial (“TOPAZ ...
Clearside Biomedical Clears Hurdle For Late-Stage Eye Disease StudySeeking Alpha

all 84 news articles »

National Institutes of Health (press release)

Avastin as effective as Eylea for treating central retinal vein occlusion
National Institutes of Health (press release)
Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion (CRVO), according to a clinical trial funded by the National Eye Institute (NEI), part ...

and more »

MD Magazine

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure
MD Magazine
Eleven patients had at least an eye with branch retinal vein occlusion. Ten eyes had age-related macular degeneration (AMD), 7 had proliferative diabetic retinopathy, 6 had central retinal vein occlusion, 5 had central serous chorioretinopathy, and 3 ...


Bel Marra Health

Retinal Artery Occlusion Increases the Risk of Atrial Fibrillation: Study
Bel Marra Health
Although there appears to be a connection between patients with retinal artery or vein occlusions and atrial fibrillation (a common type of irregular heartbeat), atrial fibrillation is not listed among the current risk factors for retinal artery ...


Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein ...
Digital Journal
The Global Retinal Vein Occlusion Market is expected to grow at a CAGR of 11.2% during the forecast period 2017-2023. Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is ...

and more »

Medscape

Should We WAVE Goodbye to Laser?
Medscape
There were no significant differences between the monotherapy and combination therapy groups in terms of mean gains in best corrected visual acuity or central retinal thickness after 1 year. Treatment burden was similar between the monotherapy and ...

» Load more